“One of the Harder Decisions”: Adjuvant Therapy for Stage II Melanoma
Source: Oncology News Central, April 2025
Two anti-PD-1 agents are currently approved for adjuvant therapy for patients with stage II melanoma. Experts say that treatment decisions for these patients are not always clear cut and that individual factors weigh in heavily. Listen as Allison Betof Warner, MD, PhD, from Stanford University, Rodabe N. Amaria, MD, from the University of Texas MD Anderson Cancer Center, and Sapna Patel, MD, from the University of Colorado, discuss the results of the CheckMate 238 trial and how those findings inform their care decisions, as well as how they approach complex discussions with these patients.